Tempest Therapeutics announces 2024 annual meeting voting results

Tempest Therapeutics, Inc.

Stockholders elected Stephen Brady, Michael Raab, and Ronit Simantov as Class III directors for three-year terms.
Advisory vote on named executive officer compensation passed with 7,466,910 for, 167,307 against, 275,440 abstentions.
Ratification of Ernst & Young as independent auditor for FY2024 approved with 14,040,756 for, 132,300 against, 21,465 abstentions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.